. Age--adjusted observed/expected ratios for the underlying cause of death (UCD) when GCA was a non--underlying cause of death (NUCD) Data are presented as observed/expected ratio (95 % confidence interval).
Introduction Giant--cell arteritis (GCA) is a large--vessel vasculitis usually affecting individuals over 50 years old, typically presenting with unilateral or bilateral headache, myalgias, fatigue, fever, weight loss, and sometimes acute vision loss [1] . It is frequently associated with polymyalgia rheumatica (PMR), which represents either a different manifestation of the same disease or overlapping conditions. Both diseases are associated with an inflammatory state with an increased erythrocyte sedimentation rate (ESR) and/or C--reactive protein (CRP), and the treatment relies mainly on corticosteroids, usually prescribed for a prolonged period. GCA seems to affect predominantly European populations, especially those of northern European descent, and is slightly more common in women than in men, with a lifetime risk of GCA estimated at 1.0% in women versus 0.5% in men [2, 3] . GCA is the most frequent primary vasculitis with an estimated incidence in the United States of 18 per 100,000, but data based on recent studies suggest that GCA incidence has stabilized or even decreased in recent years [4, 5] . Data regarding GCA mortality are controversial. A recent meta--analysis including 17 studies found no difference in long--term mortality between GCA patients and the general population (mortality odds ratio of 1.03), except in GCA patients recruited through a hospital setting (mortality odds ratio of 1.61), especially in the first two years following GCA diagnosis [6] . Mortality in GCA has been attributed to specific complications of the disease, particularly aortic aneurysms and cerebrovascular events associated with a lower survival [5, 7, 8] . Some studies also showed increased cardiovascular mortality and increased mortality due to infectious diseases in GCA patients compared with general population [9, 10] .
To better characterize mortality causes in GCA, we examined data from death certificates cause--of--death (MCOD) analysis, we calculated age--adjusted mortality rates for GCA, examined differences in mortality rates according to age and gender and recorded the underlying causes of death (UCD).
Methods

Data extraction
Data were extracted from the Institut National de la Statistique et des études économiques certificates that mentioned GCA either as the UCD or a NUCD. Only data from decedents aged ⩾18 years were analyzed.
Statistical analysis
All death certificates that listed GCA as the UCD or NUCD, whatever its place on the death certificate, were considered in the MCOD analysis. Gender and age at time of death were extracted. Direct age standardization with the general French population as a reference was applied to calculate mortality rates and estimated by year and for the study period. Mortality rates were categorized according to age group for the entire study period. Categorical variables are presented as absolute values (with percentages), whereas continuous variables are shown as the mean ± standard deviation (SD). The numbers of deaths were compared according to gender, age and the cause of death (UCD or NUCD) using the chi--squared or Fisher's exact test. Proportions of GCA listed either as the UCD or a NUCD were studied over time, with the linear trend tested over time. Linear regression and t--tests were used to compare the age at death by year and gender, respectively. Linear regressions were used to compare standardized mortality rates overall by gender and age range. Differences were considered statistically significant when p<0.05. R software version 3.0.2 (www.r--project.org/foundation/) was used for the statistical analyses.
Results
Numbers of deaths with GCA in France between 20015 and 2014
Between 2005 and 2014, 5,311,098 adults died in France. Among them, the CépiDc recorded 4,628 death certificates reporting a diagnosis of GCA as UCD or NUCD. The absolute numbers of deaths with GCA listed as UCD or NUCD, stratified by year during the study period, are shown in Table 1 . The mean number of annual deaths was 462 (±33.4) and 51.2% of them occurred in hospital. The mean age of death was 86 (±6.8) years: 84.6 (±6.9) years in men and 86.7 (±6.6) years in women (p < 0.001). Throughout the study period, the mean age of death was significantly increased (r=0.17, p<0.0001) (Figure 1) , more in men (r=0.21, p=0.001) than in women (r=0.15, p=0.001). We observed that 99.4% of all GCA--related deaths occurred after 65 years and 62.6% after 85 years. There was no significant difference with the age repartition of death in the general population (p=0.26), according to the year of death. The ratio of females to males was 2.4 (1,372 men versus 3,256 women) and remained stable throughout the study period.
Age--standardized mortality rate in GCA
The overall age--standardized mortality rate (ASMR) among GCA patients was 7.2 per million and remained stable between 2005 and 2014 (r=--3.3, p=0.056) ( Table 1) . However, for men, ASMR decreased significantly throughout the study period (r=--4, p=0.003) (Figure 2) . pneumonia, an O/E ratio > 1 was also observed between 65 and 85 years (O/E ratio = 1.5, p=0.04). An O/E ratio >1 in GCA--associated mortality was observed for cerebrovascular disease between 65 and 85 years (O/E ratio = 2.4, p<0.001) and after 85 years (O/E ratio = 1.2, p=0.01) and for hematologic malignancy between 65 and 85 years (O/E ratio = 1.4, p<0.001).
Discussion
Using the CépiDc database containing all French death certificates, we found that there was no significant difference in the age repartition of death when GCA was mentioned in the death certificate compared to that of the general population, suggesting that GCA is associated with a survival reflecting the age incidence of this disease. These results are consistent with a recent international meta--analysis that found that long--term mortality was not increased in GCA [3, 6] . In a Northern Italian study, no significant differences in mortality rates were observed between GCA and non--GCA subjects [11] . Moreover, no significant differences in the cause of death were observed comparing GCA patients to non--GCA subjects. Conversely, in a Danish study, the relative risk of death in patients diagnosed with GCA compared to the general population was 1.17 (95% CI 1.01, 1.36) and 1.22 (95% CI 1.05, 1.41) 0--2 years and >10 years after diagnosis, respectively, whereas they observed no increased mortality during the follow--up period of 2--10 years [12] . In the Swedish study, mortality was significantly increased over the first 2 years after GCA diagnosis but not with longer follow--up. The estimated excess mortality was greater in women and in patients aged ≤70 years at diagnosis [4] . Recently, a UK study found that compared with non--vasculitis patients, GCA patients had increased mortality during the first year following diagnosis but not >5 years after the diagnosis [13] . GCA patients diagnosed before age 65 had the highest mortality risk during the first year following diagnosis (adjusted HR=2.32, 95% CI 1.60--3.35). The design of the present study, which was not longitudinal, could not allow assessing the time between GCA diagnosis and death on GCA mortality.
In our study, we found that the mortality risk did not differ substantially by sex or calendar year, as was the case in the UK study [13] .
In our study, GCA was considered the underlying cause of death in 27% of patients with GCA mentioned in the death certificates. The most common associated diseases were cardiovascular disease and infectious diseases. These associated diseases are the most commonly reported in GCA epidemiologic studies. An Australian study found 71 deaths among 225 patients with biopsy--proven GCA and deaths from cardiovascular causes (45%)
were the most common, followed by infection (17%) and cancer (17%) [14] .
Increased cardiovascular mortality has been reported in GCA in 2 different settings. Some cardiovascular complications, including aortic aneurysms and ischemic strokes are predominantly associated with mortality in the early phase of the disease, usually in the 2 years after GCA diagnosis, suggesting a prevailing role of inflammatory mechanisms directly related to the vasculitis [12, 15] . In previous studies, ischemic strokes were a leading cause of death during GCA [8] . In the Danish study, the increased mortality during the first 2 years of follow--up was mainly due to diseases of the circulatory system, including aortic aneurisms [12] . In a large US study from 1950 to 2009, patients with GCA and aortic manifestations had a higher than expected number of deaths from cardiovascular and pulmonary causes than those of the general population, and manifestations were associated with increased mortality in GCA patients (HR=3.4; 95% CI 2.2 to 5.4) [5] . Cardiovascular complications may also occur after the 2 first years of the disease and may be driven by prolonged corticosteroid treatment [4] . Venous thrombosis (VT) and pulmonary embolism (PE) were also reported as a common feature during GCA [16] . In our study, we found that VT and PE accounted for 150 cases over 10 years, as the UCD or NUCD. VT and PE may be limited to GCA in--patients, who typically have a low mortality rate [17] .
Infectious complications have been reported with a higher frequency in GCA, particularly in the first year after GCA diagnosis and have been associated with older age, pre--existing diabetes and prolonged use of corticosteroids [10] . In a French prospective study, severe infections were more common among patients with GCA during the first year after diagnosis compared to general population controls. In particular, septic shock and infectious colitis were more common among the patients with GCA, and mortality caused by infections was higher in patients with GCA than in the controls [10] . In our study, a positive association (O/E ratio >1, GCA being listed as the UCD or NUCD) was observed between GCA and pneumonia and GCA and tuberculosis. This association was stronger before 85 years and decreased with age. In a recent study using death certificates in France, deaths from cardiovascular and potentially treatment--related causes were also overrepresented in decedents with GCA [18] . Our study has several limitations. Since the assessment of UCD and NCUD on the death certificate is left to the physician's judgment, GCA may not have been declared for patients with a long time from diagnosis to death or in patients considered in remission. Moreover, the physicians did not mention GCA if they consider that if has not contributed to death. On the other hand, for patients with more severe disease, GCA was probably more likely to be reported as UCD or NUCD. The distinction between UCD and NUCD is also difficult to appraise in GCA. Some individuals may consider complications such as aortic aneurysm or ischemic stroke as UCD, while others consider them NUCD.
Conclusions
Despite limitations, our study suggests that overall mortality is not strongly increased in GCA patients and remained stable between 2005 and 2014, suggesting that there was no improvement in the treatments during the period. Most common comorbidities were cardiovascular and infectious diseases, which can both be considered complications of GCA but also long--term complications of GCA treatment, especially corticosteroid treatment.
Improving our knowledge on mortality in GCA will help determine important actions to prevent long--term complications of the disease. 
